Paval D Robert, Di Virgilio Thomas G, Skipworth Richard J E, Gallagher Iain J
Faculty of Health Sciences & Sport, University of Stirling, Stirling, United Kingdom.
Clinical Surgery, Edinburgh Medical School and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Front Oncol. 2024 Feb 28;14:1198555. doi: 10.3389/fonc.2024.1198555. eCollection 2024.
Intelectin-1 (ITLN1) is an adipokine with multiple physiological functions, including a role in tumour formation and development. Previous research reported variable ITLN1 levels for cancer patients and healthy individuals. This study aimed to compare ITLN1 concentrations between controls and cancer patients and to determine the adipokine's physiological level.
Five databases were searched in January 2022 for studies that measured the level of ITLN1 in adults that were healthy or diagnosed with any type of cancer. After title, abstract and full-text screening, the methodological quality of the studies was assessed. The extracted data were meta-analysed using the R language and Bayesian statistical techniques.
Overall, 15 studies compared circulating ITLN1 levels between healthy individuals (n=3424) and cancer patients (n=1538), but no differences were observed between these studies. ITLN1 was not different between groups in an analysis that evaluated high-quality studies only (n=5). The meta-analysis indicated considerably higher ITLN1 levels in gastrointestinal (i.e., colorectal, pancreatic, gastric) cancer compared to controls, while the other cancer types did not demonstrate differences between groups. The mean ITLN1 level of healthy individuals was 234 ± 21ng/ml (n=136), while the average value in high-quality studies (n=52) was 257 ± 31ng/ml.
Different types of cancer showed different circulating ITLN1 patterns. Circulating ITLN1 concentration was higher in gastrointestinal cancer compared to controls, with strong support from the meta-analytical model. Our analysis also determined the mean ITLN1 level in healthy individuals; this is a crucial starting point for understanding how this cytokine associates with diseases. Two-thirds of the studies were of low methodological quality and thus, future work in this field must focus on improved methods.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=303406, identifier CRD42022303406.
凝集素-1（ITLN1）是一种具有多种生理功能的脂肪因子，在肿瘤形成和发展中发挥作用。先前的研究报道了癌症患者和健康个体中ITLN1水平的差异。本研究旨在比较对照组和癌症患者之间的ITLN1浓度，并确定该脂肪因子的生理水平。
2022年1月检索了五个数据库，以查找测量健康或诊断为任何类型癌症的成年人中ITLN1水平的研究。经过标题、摘要和全文筛选后，评估了研究的方法学质量。使用R语言和贝叶斯统计技术对提取的数据进行荟萃分析。
总体而言，15项研究比较了健康个体（n = 3424）和癌症患者（n = 1538）之间的循环ITLN1水平，但这些研究之间未观察到差异。在仅评估高质量研究（n = 5）的分析中，各亚组之间的ITLN1没有差异。荟萃分析表明，与对照组相比，胃肠道（即结肠、胰腺、胃）癌患者的ITLN1水平显著更高，而其他癌症类型的亚组之间没有差异。健康个体的平均ITLN1水平为234±21ng/ml（n = 136），而高质量研究（n = 52）中的平均值为257±31ng/ml。
不同类型的癌症表现出不同的循环ITLN1模式。与对照组相比，胃肠道癌患者的循环ITLN1浓度更高，荟萃分析模型提供了有力支持。我们的分析还确定了健康个体的平均ITLN1水平；这是理解这种细胞因子如何与疾病相关联的关键起点。三分之二的研究方法学质量较低，因此，该领域未来的工作必须侧重于改进方法。
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=303406，标识符CRD42022303406。
Zotero 插件
